ArticleGene therapy2009
Development of inducible EIAV-based lentiviral vector packaging and producer cell lines.
Article in Gene therapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 50 citations in OpenAlex.
- Lentiviral vector packaging and producer cell lines yield titers equivalent to the industry-standard four-plasmid process.Molecular therapy. Methods & clinical development · 2024Article
- Development of KoRV-pseudotyped lentiviral vectors for efficient gene transfer into freshly isolated immune cells.Gene therapy · 2024Article
- Quasi-perfusion studies for intensified lentiviral vector production using a continuous stable producer cell line.Molecular therapy. Methods & clinical development · 2024Article
- Packaging cells for lentiviral vectors generated using the cumate and coumermycin gene induction systems and nanowell single-cell cloning.Molecular therapy. Methods & clinical development · 2023Article
- Lentiviral Vector Bioprocessing.Viruses · 2021Review
- HEK293 Cell Line as a Platform to Produce Recombinant Proteins and Viral Vectors.Frontiers in bioengineering and biotechnology · 2021Review
- Rapid Lentiviral Vector Producer Cell Line Generation Using a Single DNA Construct.Molecular therapy. Methods & clinical development · 2020Article
- Large-Scale Production of Lentiviral Vectors: Current Perspectives and Challenges.Pharmaceutics · 2020Review
- Review
- Preclinical Development of Autologous Hematopoietic Stem Cell-Based Gene Therapy for Immune Deficiencies: A Journey from Mouse Cage to Bed Side.Pharmaceutics · 2020Review
- Mass spectrometry analysis reveals differences in the host cell protein species found in pseudotyped lentiviral vectors.Biologicals : journal of the International Association of Biological Standardization · 2018Article
- Optogenetic Tractography for anatomo-functional characterization of cortico-subcortical neural circuits in non-human primates.Scientific reports · 2018Article
- Genome editing for scalable production of alloantigen-free lentiviral vectors forEMBO molecular medicine · 2017Article
- Article
- Production of lentiviral vectors.Molecular therapy. Methods & clinical development · 2016Review
- Construction of stable packaging cell lines for clinical lentiviral vector production.Scientific reports · 2015Article
- EIAV-based retinal gene therapy in the shaker1 mouse model for usher syndrome type 1B: development of UshStat.PloS one · 2014Article
- Development of an equine-tropic replication-competent lentivirus assay for equine infectious anemia virus-based lentiviral vectors.Human gene therapy methods · 2012Article
- Current translational and clinical practices in hematopoietic cell and gene therapy.Cytotherapy · 2012Review
- Parkinson's disease.Sub-cellular biochemistry · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Large-scale production of gene therapeutics comprising equine infectious anaemia virus (EIAV) -based lentiviral vectors (LVs) would benefit from the development of producer cell lines enabling the generation of larger quantities of vector than achievable by transient systems. Such cell lines would contain three vector components (Gag/Pol, VSV-G envelope and genome expression constructs). As the vesicular stomatitis virus (VSV-G) envelope protein is cytotoxic, its expression must be regulated. It is also desirable to regulate Gag/Pol expression to minimise metabolic burden on the cell. The Tet repressor (TetR) system was selected to regulate expression of VSV-G and Gag/Pol, necessitating the introduction of a fourth construct, encoding TetR, into the cell line. We have generated an inducible packaging cell line that shows tight control of the packaging components, and high-titre vector production on transient transfection of the EIAV genome. The cell line is stable for at least 7 weeks in the absence of selective pressure. To verify that this packaging cell line can support the generation of producer cell lines it was transfected stably with an EIAV genome cassette encoding ProSavin; a gene therapeutic for Parkinson's disease. Producer cell lines were generated, which on induction, yielded ProSavin with titres comparable to the transient system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.